Journal article
Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis
Robert J Commons, Julie A Simpson, Kamala Thriemer, Mohammad S Hossain, Nicholas M Douglas, Georgina S Humphreys, Carol H Sibley, Philippe J Guerin, Ric N Price
Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2019
Abstract
BACKGROUND: A 14-day course of primaquine is used for radical cure of Plasmodium vivax and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after treatment of Plasmodium falciparum with commonly used antimalarial drugs to assess the potential benefits of radical cure for all patients with uncomplicated malaria in co-endemic regions. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, Web of Science, and the Cochrane Database of Systematic Reviews for prospective clinical studies in any language, published between Jan 1, 1960, and Jan 5, 2018, assessing drug efficacy in patients with uncomplicated P falciparum malaria in countries co..
View full abstractRelated Projects (2)
Grants
Awarded by Australian NHMRC Senior Research Fellowship
Awarded by OPRA clinical trial fund - Bill & Melinda Gates Foundation
Awarded by Australian Centre for Research Excellence on Malaria Elimination (ACREME) - National Health and Medical Research Council of Australia
Funding Acknowledgements
RJC is supported by a Postgraduate Australian National Health and Medical Research Council (NHMRC) Scholarship and a Royal Australasian College of Physicians NHMRC Kincaid-Smith Scholarship. RNP is a Wellcome Trust Senior Fellow in Clinical Science (200909). JAS is funded by an Australian NHMRC Senior Research Fellowship (1104975). MSH is funded by the Special Programme for Research and Training in Tropical Diseases. KT is funded by the Asia Pacific Malaria Elimination Network (APMEN) and OPRA clinical trial funding, supported by the Bill & Melinda Gates Foundation (OPP1164105 and OPP1054404). The WorldWide Antimalarial Resistance Network is funded by Bill & Melinda Gates Foundation and ExxonMobil Foundation grants. This work was supported by the Australian Centre for Research Excellence on Malaria Elimination (ACREME), funded by the National Health and Medical Research Council of Australia (APP 1134989). The funders did not participate in the study protocol development, the analysis, or the writing of the paper. We would like to thank Amalia Karahalios and Dennis Shanks for their support and advice on the analysis and interpretation of the study.